Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 6Glioma 3Glioblastoma 2Stomach Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Neuroma, Acoustic 1Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Cerebrovascular Disorders 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 115Radiotherapy 63Magnetic Resonance Spectroscopy 30Carboplatin 30Bevacizumab 30Carmustine 28Filgrastim 23Surgical Procedures, Operative 22Irinotecan 22Radiation 18Lomustine 17Vincristine 15Etoposide 15Specimen Handling 13Peripheral Blood Stem Cell Transplantation 13O(6)-benzylguanine 13Radiotherapy, Intensity-Modulated 12Procarbazine 11Erlotinib Hydrochloride 11Cyclophosphamide 11Chemotherapy, Adjuvant 11sargramostim 10Thiotepa 10Cisplatin 10Flucytosine 9Everolimus 9antineoplaston AS 2-1 8antineoplaston A10 8Granulocyte Colony-Stimulating Factor 8Vorinostat 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Astrocytoma × Fluorescein × CNS × Clear all
NCT02540135 2018-07-20

Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma

University of Colorado, Denver

Phase NA Withdrawn
CNS

Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡